title: [Extrapancreatic effects of GLP-1 receptor agonists: an open window towards new treatment goals in type 2 diabetes].
abstract: The wide ubiquity of GLP-1 receptors in the body has stimulated the search for different extrapancreatic actions of GLP-1 and its receptor agonists. Thus, severe cardioprotective effects directed on myocardial ischaemia and dysfunction as well as diverse antiaterogenic actions have been reported. Also, native and GLP-1 receptor agonists have demonstrated significant beneficial effects on liver steatosis and fibrosis and on neuronal protection in experimental models of Alzheimer, and Parkinson's disease as well as on cerebral ischaemia. Recent evidences suggest that these drugs may also be useful for prevention and treatment of diabetic retinopathy, nephropathy and peripheral neuropathy. Good results have also been reported in psoriasis. Despite we still need confirmation that these promising effects can be applied to clinical practice, they offer new interesting perspectives for treatment of type 2 diabetes associated complications and give to GLP-1 receptor agonists an even more integral position in diabetes therapy.
authors.affiliation: Departamento de Endocrinología y Nutrición, Clínica Universidad de Navarra, Pamplona, España. Electronic address: jsalvador@unav.es.
authors.forename: Javier
authors.initials: J
authors.lastname: Salvador
authors.affiliation: Departamento de Endocrinología y Nutrición, Clínica Universidad de Navarra, Pamplona, España.
authors.forename: Patricia
authors.initials: P
authors.lastname: Andrada
mesh_terms: D000544:Alzheimer Disease / Q000209:etiology / Q000517:prevention & control; D002545:Brain Ischemia / Q000209:etiology / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000209:etiology / Q000517:prevention & control; D003929:Diabetic Neuropathies / Q000209:etiology / Q000517:prevention & control; D003930:Diabetic Retinopathy / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D054795:Incretins / Q000627:therapeutic use*; D008107:Liver Diseases / Q000209:etiology / Q000517:prevention & control; D010300:Parkinson Disease / Q000209:etiology / Q000517:prevention & control; D010347:Patient Care Planning; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
chemical_list: D007004:Hypoglycemic Agents; D054795:Incretins; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
keywords: Agonistas GLP-1; Cardioprotección; Cardioprotection; Efectos extrapancreáticos; Exenatida; Exenatide; Extrapancreatic effects; GLP-1 receptor agonists; Hepatoprotección; Hepatoprotection; Incretinas; Incretins; Liraglutida; Liraglutide; Lixisenatida; Lixisenatide; Neuroprotección; Neuroprotection